IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 1636 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
   Next article
   Previous article 
   Table of Contents
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Article in PDF (103 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
    References

 Article Access Statistics
    Viewed4543    
    Printed40    
    Emailed0    
    PDF Downloaded93    
    Comments [Add]    

Recommend this journal

 
LETTER TO EDITOR
Year : 2004  |  Volume : 70  |  Issue : 4  |  Page : 248-249

Response by Dr. Ramam


Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi - 110029, India

Correspondence Address:
Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi - 110 029, India
mramam@hotmail.com



How to cite this article:
Ramam M. Response by Dr. Ramam. Indian J Dermatol Venereol Leprol 2004;70:248-9


How to cite this URL:
Ramam M. Response by Dr. Ramam. Indian J Dermatol Venereol Leprol [serial online] 2004 [cited 2019 Aug 19];70:248-9. Available from: http://www.ijdvl.com/text.asp?2004/70/4/248/12370


Sir,
The suggestions made by Gandhi et al will have to be considered by centers administering pulse therapy and implemented if considered beneficial and feasible. It would be ideal to compare the proposed changes to the original schedule in a randomised, controlled trial. Carefully kept records will be needed to document the time to remission, the duration of remission with treatment and the relapse-free period after stopping therapy: outcomes of importance to patients and dermatologists alike. I would like to make a comment on the utility of immunofluorescence testing in determining the length of treatment. There are few situations where indirect immunofluorescence (IIF) testing is of any significant diagnostic value in pemphigus. Its role in predicting prognosis is also limited. Direct immunofluorescence (DIF) testing fares better in predicting relapse-free remissions but is not reliable enough to be useful in everyday clinical practice.[1],[2] ELISA for antibodies to desmoglein 3 and desmoglein 1 is a relatively new test and time will tell if it will have much application in prognosis though this appears unlikely from previous experience with IIF. For the present, it appears that we will have to continue our search for reliable predictors of the response to treatment. 

   References Top

1.Judd KP, Lever WF. Correlation of antibodies in skin and serum with disease severity in pemphigus. Arch Dermatol 1979;115:428-32.  Back to cited text no. 1  [PUBMED]  
2.Pasricha JS. AIIMS experience. In: Pasricha JS, Pulse therapy in pemphigus and other diseases, New Delhi, 1998; 2nd Ed, New Delhi: Pulse Therapy and Pemphigus Foundation, 2000. p. 21-40.  Back to cited text no. 2    

 

Top
Print this article  Email this article
Previous article Next article

    

Online since 15th March '04
Published by Wolters Kluwer - Medknow